ERYTECH adds a new product candidate to its Cancer Metabolism development portfolio Post author:admERY Post published:April 9, 2014 Post category:Newsroom ERYTECH announces the addition of a new product development candidate, erymethionase, to the company’s Cancer Metabolism product pipeline. You Might Also Like ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer December 14, 2020 ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia September 10, 2013 ERYTECH to Host on May 7, 2020 First Quarter Conference Call and Business Update April 30, 2020
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer December 14, 2020
ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia September 10, 2013